Asymchem has announced a strategic partnership agreement to provide LaNova Medicines with one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration.
 
The collaboration between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives. This partnership will take full advantage of Asymchem’s recently completed biological CDMO service platform and production base at Shanghai Jinshan, where Asymchem is already undertaking R&D and production services for a number of early IND and clinical phase projects of biological drugs. The platform can provide R&D and production services including monoclonal antibodies, double antibodies and ADC drugs. 
 
“With the advent of the ADC drug research and development wave, ADC-related businesses have exploded,” observed Asymchem chief operating officer (COO) Yang Rui, who attended the signing ceremony in Shanghai. “In the future, we expect to build ADC pilot and commercial production facilities to further enhance Asymchem’s capabilities with ADC drugs.”
 
Antibody-drug conjugates (ADCs) are a promising class of targeted drugs in which drug molecules are linked to antibodies that selectively attach to the surface of cancer cells while avoiding effects on nearby healthy cells, dramatically reducing side effects. More than 100 clinical trials are underway studying the effectiveness of ADCs in treating blood, lung, breast, brain and other cancers. 
 
Rui said the partnership was a logical next step for Asymchem as the CDMO continues to expand its capabilities and service into new business areas to offer pharmaceutical and biotech companies innovative and sustainable solutions. 
 
“This cooperative venture with LaNova will bring more valuable new drugs to the treatment of cancer and other diseases while improving the lives of patients,” Rui added. “It’s an exciting time to be at the forefront of drug development.”